At the 2026 American Society for Clinical Oncology Annual Meeting, UT MD Anderson researchers are presenting five breakthrough studies that represent a fundamental shift in how cancer is treated: not as a single disease, but as hundreds of distinct genetic puzzles, each demanding its own precision solution.
Cancer treatment has long relied on a one-size-fits-all approach, but genomic medicine is upending that model. When a patient's tumor carries a specific mutation—EGFR, BRAF, IDH1, FLT3—their treatment can now be tailored to attack that exact vulnerability while sparing healthy cells. This matters profoundly because many common cancers develop resistance to standard therapies. At MD Anderson, clinicians like Xiuning Le, associate professor of Thoracic/Head & Neck Medical Oncology, are tackling this head-on with the Phase 1 SOLARA trial, testing a new mutant-selective OMNI-EGFR inhibitor for non-small cell lung cancer. Early results show the therapy precisely targets tumor-driving EGFR mutations while leaving healthy cells unharmed, a breakthrough for patients whose cancers have previously resisted treatment.
Small cell lung cancer, an aggressive disease with historically poor prognosis, is seeing new hope through a different precision strategy. Lauren Byers, professor of Thoracic/Head & Neck Medical Oncology, is sharing results from a clinical trial of ABBV-706, an antibody-drug conjugate that targets SEZ6, a protein commonly overexpressed on small cell lung cancer cells. The trial shows promising overall survival benefits as a standalone therapy, combined with immunotherapy, and even for patients beyond first-line treatment—suggesting this approach could reshape outcomes for one of oncology's most difficult cancers.
The work extends across cancer types. Van Morris, associate professor of Gastrointestinal Medical Oncology, is presenting data from a Phase 3 trial for BRAF V600E-mutated colorectal cancer. Though the triplet combination of chemotherapy and immunotherapy did not improve survival as hoped, the trial generated critical insights into why this aggressive colorectal subtype resists current therapies and identified new biomarkers that could guide future treatment strategies. This reflects the honest science behind precision medicine: even negative results advance the field by narrowing the search space.
In hematologic malignancies, the advances are equally striking. Jennifer Marvin-Peek, a fellow in Cancer Medicine, is presenting results from a multicenter Phase 1b/2 trial testing a novel triplet therapy—azacitidine, venetoclax, and ivosidenib—for IDH1-mutated acute myeloid leukemia. While existing two-drug combinations have helped, many patients still don't respond or relapse. This triplet demonstrated high response rates with safety comparable to doublet combinations, potentially opening doors for patients whose leukemias have resisted current standard care.
The conference also features work on FLT3-mutated acute myeloid leukemia, another particularly aggressive subset where Musa Yilmaz, associate professor of Leukemia, is sharing new therapeutic approaches designed to overcome resistance to the standard decitabine-venetoclax combination.
What ties these studies together is a shared conviction: that understanding a tumor's genetic fingerprint doesn't just improve treatment—it transforms outcomes. By matching patients to therapies designed for their specific mutations, MD Anderson researchers are moving beyond the era of trial-and-error oncology into an age of rational, mutation-matched precision care. For patients living with these historically hard-to-treat cancers, that shift represents something far more than academic progress. It represents hope grounded in science.